BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22158053)

  • 1. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.
    Sahasrabuddhe VV; Parham GP; Mwanahamuntu MH; Vermund SH
    Cancer Prev Res (Phila); 2012 Jan; 5(1):11-7. PubMed ID: 22158053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for cancer in low- and middle-income countries.
    Sankaranarayanan R
    Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus-based cervical precancer screening with visual inspection with acetic acid triage to achieve same-day treatments among women living with human immunodeficiency virus infection: test-of-concept study in Ibadan, Nigeria.
    Awolude OA; Oyerinde SO; Ayeni AO; Adewole IF
    Pan Afr Med J; 2021; 40():48. PubMed ID: 34795828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of cervical neoplasia in HIV-infected women in India.
    Joshi S; Sankaranarayanan R; Muwonge R; Kulkarni V; Somanathan T; Divate U
    AIDS; 2013 Feb; 27(4):607-15. PubMed ID: 23079814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.
    Njue JK; Muturi M; Kamau L; Lwembe R
    Biomed Res Int; 2022; 2022():1930102. PubMed ID: 36164451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer screening in high- and low-resource countries: implications and new developments.
    Hoppenot C; Stampler K; Dunton C
    Obstet Gynecol Surv; 2012 Oct; 67(10):658-67. PubMed ID: 23112073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
    Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
    Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer screening in low- and middle-income countries.
    Ditzian LR; David-West G; Maza M; Hartmann B; Shirazian T; Cremer M
    Mt Sinai J Med; 2011; 78(3):319-26. PubMed ID: 21598259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review.
    Mapanga W; Girdler-Brown B; Feresu SA; Chipato T; Singh E
    Syst Rev; 2018 Nov; 7(1):198. PubMed ID: 30447695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
    PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
    Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
    Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
    Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
    Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triage of Women Testing Positive With the careHPV Test on Self-Collected Vaginal Samples for Cervical Cancer Screening in a Low-Resource Setting.
    Poli UR; Gowrishankar S; Swain M; Jeronimo J
    J Glob Oncol; 2018 Sep; 4():1-7. PubMed ID: 30241206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
    Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
    Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
    Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.